Clearpoint Neuro Stock Analysis

CLPT Stock  USD 5.32  0.18  3.27%   
Clearpoint Neuro is undervalued with Real Value of 7.61 and Target Price of 14.5. The main objective of Clearpoint Neuro stock analysis is to determine its intrinsic value, which is an estimate of what Clearpoint Neuro is worth, separate from its market price. There are two main types of Clearpoint Neuro's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Clearpoint Neuro's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Clearpoint Neuro's stock to identify patterns and trends that may indicate its future price movements.
The Clearpoint Neuro stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Clearpoint Neuro is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Clearpoint Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Clearpoint Neuro's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearpoint Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.

Clearpoint Stock Analysis Notes

About 30.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.9. Clearpoint Neuro last dividend was issued on the 27th of July 2016. The entity had 1:40 split on the 27th of July 2016. ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Clearpoint Neuro operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 80 people. For more info on Clearpoint Neuro please contact Joseph Burnett at 888 287 9109 or go to https://www.clearpointneuro.com.

Clearpoint Neuro Quarterly Total Revenue

6.81 Million

Clearpoint Neuro Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Clearpoint Neuro's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Clearpoint Neuro or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Clearpoint Neuro generated a negative expected return over the last 90 days
Clearpoint Neuro has high historical volatility and very poor performance
The company reported the previous year's revenue of 23.95 M. Net Loss for the year was (22.09 M) with profit before overhead, payroll, taxes, and interest of 13.53 M.
Clearpoint Neuro currently holds about 45.14 M in cash with (13.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84.
Clearpoint Neuro has a poor financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

Clearpoint Neuro Upcoming and Recent Events

Earnings reports are used by Clearpoint Neuro to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Clearpoint Neuro previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Clearpoint Largest EPS Surprises

Earnings surprises can significantly impact Clearpoint Neuro's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-03-01
2022-12-31-0.2-0.180.0210 
2021-11-09
2021-09-30-0.16-0.18-0.0212 
2022-05-11
2022-03-31-0.2-0.170.0315 
View All Earnings Estimates

Clearpoint Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Clearpoint Neuro is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Clearpoint Neuro backward and forwards among themselves. Clearpoint Neuro's institutional investor refers to the entity that pools money to purchase Clearpoint Neuro's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Parsons Capital Management Inc2023-12-31
106.2 K
Goldman Sachs Group Inc2023-12-31
93.1 K
Citadel Advisors Llc2023-09-30
86.2 K
Bridgeway Capital Management, Llc2023-12-31
67 K
Charles Schwab Investment Management Inc2023-12-31
62.8 K
Bank Of New York Mellon Corp2023-12-31
62 K
Commonwealth Equity Services Inc2023-12-31
59.2 K
Ubs Group Ag2023-12-31
53.5 K
Royce & Associates, Lp2023-12-31
53.1 K
Blackrock Inc2023-12-31
1.5 M
Vanguard Group Inc2023-12-31
1.3 M
Note, although Clearpoint Neuro's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Clearpoint Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 148.88 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Clearpoint Neuro's market, we take the total number of its shares issued and multiply it by Clearpoint Neuro's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Clearpoint Profitablity

Clearpoint Neuro's profitability indicators refer to fundamental financial ratios that showcase Clearpoint Neuro's ability to generate income relative to its revenue or operating costs. If, let's say, Clearpoint Neuro is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Clearpoint Neuro's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Clearpoint Neuro's profitability requires more research than a typical breakdown of Clearpoint Neuro's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.92) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.69) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.69.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.53)(0.56)
Return On Capital Employed(0.64)(0.67)
Return On Assets(0.52)(0.54)
Return On Equity(1.04)(0.99)

Management Efficiency

Clearpoint Neuro has return on total asset (ROA) of (0.2859) % which means that it has lost $0.2859 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7609) %, meaning that it created substantial loss on money invested by shareholders. Clearpoint Neuro's management efficiency ratios could be used to measure how well Clearpoint Neuro manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.56 in 2024. Return On Capital Employed is likely to drop to -0.67 in 2024. At this time, Clearpoint Neuro's Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 4.7 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 0.86  0.90 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 0.82  0.86 
Enterprise Value Over EBITDA(7.52)(7.90)
Price Book Value Ratio 7.89  8.29 
Enterprise Value Multiple(7.52)(7.90)
Price Fair Value 7.89  8.29 
Enterprise Value157.9 M165.8 M
The analysis of Clearpoint Neuro's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Clearpoint Neuro's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Clearpoint Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.916

Technical Drivers

As of the 24th of April, Clearpoint Neuro shows the mean deviation of 3.01, and Risk Adjusted Performance of (0.04). Clearpoint Neuro technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Clearpoint Neuro, which can be compared to its peers. Please confirm Clearpoint Neuro market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Clearpoint Neuro is priced correctly, providing market reflects its regular price of 5.32 per share. Given that Clearpoint Neuro has information ratio of (0.10), we suggest you to validate Clearpoint Neuro's prevailing market performance to make sure the company can sustain itself at a future point.

Clearpoint Neuro Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Clearpoint Neuro middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Clearpoint Neuro. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Clearpoint Neuro Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clearpoint Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clearpoint Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clearpoint Neuro insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Clearpoint Neuro Predictive Daily Indicators

Clearpoint Neuro intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Clearpoint Neuro stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Clearpoint Neuro Corporate Filings

5th of April 2024
Other Reports
ViewVerify
F4
2nd of April 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
13th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
12th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
8th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
1st of March 2024
Prospectus used primarily for registering securities for public sale.
ViewVerify
28th of February 2024
Other Reports
ViewVerify
F4
23rd of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Clearpoint Neuro Forecast Models

Clearpoint Neuro's time-series forecasting models are one of many Clearpoint Neuro's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Clearpoint Neuro's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Clearpoint Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Clearpoint Neuro prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Clearpoint shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Clearpoint Neuro. By using and applying Clearpoint Stock analysis, traders can create a robust methodology for identifying Clearpoint entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.92)(0.97)
Operating Profit Margin(0.94)(0.98)
Net Loss(0.92)(0.97)
Gross Profit Margin 0.57  0.75 

Current Clearpoint Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Clearpoint analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Clearpoint analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
14.5Strong Buy3Odds
Clearpoint Neuro current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Clearpoint analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Clearpoint stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Clearpoint Neuro, talking to its executives and customers, or listening to Clearpoint conference calls.
Clearpoint Analyst Advice Details

Clearpoint Stock Analysis Indicators

Clearpoint Neuro stock analysis indicators help investors evaluate how Clearpoint Neuro stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Clearpoint Neuro shares will generate the highest return on investment. By understating and applying Clearpoint Neuro stock analysis, traders can identify Clearpoint Neuro position entry and exit signals to maximize returns.
Begin Period Cash Flow27.6 M
Long Term Debt9.9 M
Common Stock Shares Outstanding24.6 M
Total Stockholder Equity21.2 M
Property Plant And Equipment NetM
Cash And Short Term Investments23.1 M
Cash23.1 M
Accounts Payable393 K
Net Debt-9.2 M
50 Day M A6.5912
Total Current Liabilities7.4 M
Other Operating Expenses46.4 M
Non Current Assets Total6.5 M
Non Currrent Assets Other495 K
Stock Based Compensation6.1 M
When determining whether Clearpoint Neuro is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Clearpoint Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Clearpoint Neuro Stock. Highlighted below are key reports to facilitate an investment decision about Clearpoint Neuro Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearpoint Neuro. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Clearpoint Stock analysis

When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Global Correlations
Find global opportunities by holding instruments from different markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Is Clearpoint Neuro's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearpoint Neuro. If investors know Clearpoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearpoint Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.974
Quarterly Revenue Growth
0.316
Return On Assets
(0.29)
Return On Equity
(0.76)
The market value of Clearpoint Neuro is measured differently than its book value, which is the value of Clearpoint that is recorded on the company's balance sheet. Investors also form their own opinion of Clearpoint Neuro's value that differs from its market value or its book value, called intrinsic value, which is Clearpoint Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearpoint Neuro's market value can be influenced by many factors that don't directly affect Clearpoint Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearpoint Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearpoint Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearpoint Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.